The state of the intestinal microbiota as one of the pathogenetic factors in the development of metabolic disorders and a therapeutic target in children with obesity (literature review, own research)
DOI:
https://doi.org/10.15574/SP.2022.125.93Keywords:
intestinal microbiota, obesity, metabolic syndrome, comorbidity, childrenAbstract
The high prevalence of obesity among children and adolescents at the current stage is an important medical and social problem in pediatric practice. The presence of obesity in children is a significant risk factor for the development of metabolic disorders in the body. Pathogenetic mechanisms of the development of metabolic disorders in obese people remain to be fully understood, but the presence of a chronic inflammatory process in the body is considered to be one of the key factors in their formation. For today, many scientists are studying the state of the intestinal microbiota as one of the likely triggers of chronic inflammation and the development of metabolic changes in obese people.
The purpose - to summarize the literature data and the results of our own research on the effectiveness of the therapeutic effect of probiotic cultures on the main metabolic indicators in children with obesity.
Results and conclusions. At the current stage, scientific researches on the study the role of intestinal microbiota both as a marker of metabolic changes in the body of obese people and as a potential therapeutic target are continuing. According to systematic reviews, the level of pro-inflammatory cytokines in the body of obese people is significantly increased and pronounced dysbiotic disturbances are noted. Addition of probiotic cultures to therapy has been reported by various researchers to improve basic metabolic parameters and reduce inflammatory markers in obese people. As a result of our own research, improvements in carbohydrate and lipid metabolism indicators, the structural and functional state of the liver, and the general condition of obese children who took a synbiotic drug in complex treatment were revealed.
The research was carried out in accordance with the principles of the Helsinki Declaration. The study protocol was approved by the Local Ethics Committee of all participating institutions. The informed consent of the patient was obtained for conducting the studies.
No conflict of interests was declared by the authors.
References
Abaturov OIe, Nikulina AO. (2021). Metabolichno asotsiiovana zhyrova khvoroba pechinky u ditei. Navchalno-metodychnyi posibnyk. Dnipro: LIRA: 724.
Bluemel S, Williams B, Knight R, Schnabl B. (2016). Precision medicine in alcoholic and nonalcoholic fatty liver disease via modulating the gut microbiota. Am J Physiol Gastrointest Liver Physiol. 311 (6): 1018-1036. https://doi.org/10.1152/ajpgi.00245.2016; PMid:27686615 PMCid:PMC5206291
Bodhini D, Mohan V. (2018). Mediators of insulin resistance & cardiometabolic risk: Newer insights. Indian J Med Res. 148 (2): 127-129. https://doi.org/10.4103/ijmr.IJMR_969_18; PMid:30381534 PMCid:PMC6206760
Canfora EE, Jocken JW, Blaak EE. (2015). Short-chain fatty acids in control of body weight and insulin sensitivity. Nat Rev Endocrinol. 11: 577-591. https://doi.org/10.1038/nrendo.2015.128; PMid:26260141
Cavelti-Weder C, Babians-Brunner A, Keller C, Stahel MA, Kurz-Levin M, Zayed H et al. (2012). Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care. 35: 16-54. https://doi.org/10.2337/dc11-2219; PMid:22699287 PMCid:PMC3402269
Chambers ES, Byrne CS, Morrison DJ, Murphy KG, Preston T, Tedford C et al. (2019). Dietary supplementation with inulin-propionate ester or inulin improves insulin sensitivity in adults with overweight and obesity with distinct effects on the gut microbiota, plasma metabolome and systemic inflammatory responses: a randomised cross-over trial. Gut. 68: 1430-1438. https://doi.org/10.1136/gutjnl-2019-318424; PMid:30971437 PMCid:PMC6691855
Dominguez H, Storgaard H, Rask-Madsen C, Steffen Hermann T, Ihlemann N, Baunbjerg Nielsen D et al. (2005). Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes. J Vasc Res. 42: 517-525. https://doi.org/10.1159/000088261; PMid:16155368
Famouri F, Shariat Z, Hashemipour M, Keikha M, Kelishadi R. (2017). Effects of Probiotics on Nonalcoholic Fatty Liver Disease in Obese Children and Adolescents. J Pediatr Gastroenterol Nutr. 64: 413-417. https://doi.org/10.1097/MPG.0000000000001422; PMid:28230607
Fleischman A, Shoelson SE, Bernier R, Goldfine AB. (2008). Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care. 31: 289-294. https://doi.org/10.2337/dc07-1338; PMid:17959861 PMCid:PMC3226794
Ghoshal S, Witta J, Zhong J, De Villiers W, Eckhardt E. (2009). Chylomicrons promote intestinal absorption of lipopolysaccharides. J Lipid Res. 50: 90-97. https://doi.org/10.1194/jlr.M800156-JLR200; PMid:18815435
Gomes JMG, Costa JA, Alfenas RCG. (2017). Metabolic endotoxemia and diabetes mellitus: a systematic review. Metabolism. 68: 133-144. https://doi.org/10.1016/j.metabol.2016.12.009; PMid:28183445
Haffner SM. (2007). Abdominal adiposity and cardiometabolic risk: do we have all the answers? Am J Med. 120 (9): 10-16. Discussion S16-17. https://doi.org/10.1016/j.amjmed.2007.06.006; PMid:17720354
He X, Ji G, Jia W, Li H. (2016). Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanism and Application of Metabolomics. Int J Mol Sci. 17 (3): 300. https://doi.org/10.3390/ijms17030300; PMid:26999104 PMCid:PMC4813164
Hjorth MF, Blædel T, Bendtsen LQ, Lorenzen JK, Holm JB, Kiilerich P, Roager HM, Kristiansen K et al. (2019). Prevotella-to-Bacteroides ratio predicts body weight and fat loss success on 24-week diets varying in macronutrient composition and dietary fiber: results from a post-hoc analysis. Int J Obes. 43: 149-157. https://doi.org/10.1038/s41366-018-0093-2; PMid:29777234 PMCid:PMC6331389
Hotamisligil GS, Shargill NS, Spiegelman BM. (1993). Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 259: 87-91. https://doi.org/10.1126/science.7678183; PMid:7678183
Janssen F, Bardoutsos A, Vidra N. (2020). Obesity Prevalence in the LongTerm Future in 18 European Countries and in the USA. Obesity Facts. 1: 14. https://doi.org/10.1159/000511023; PMid:33075798 PMCid:PMC7670332
Kelishadi R, Farajian S, Safavi M, Mirlohi M, Hashemipour M. (2014). A randomized triple-masked controlled trial on the effects of synbiotics on inflammation markers in overweight children. J Pediatr. 90: 161-168. https://doi.org/10.1016/j.jped.2013.07.003; PMid:24184299
Larsen CM, Faulenbach M, Vaag A, Volund A, Ehses JA, Seifert B et al. (2007). Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med. 356: 1517-1526. https://doi.org/10.1056/NEJMoa065213; PMid:17429083
Lassenius MI, Pietilainen KH, Kaartinen K, Pussinen PJ, Syrjanen J, Forsblom C et al. (2011). Bacterial endotoxin activity in human serum is associated with dyslipidemia, insulin resistance, obesity, and chronic inflammation. Diabetes Care. 34: 1809-1815. https://doi.org/10.2337/dc10-2197; PMid:21636801 PMCid:PMC3142060
Lazar V, Ditu L-M, Pircalabioru GG, Gheorghe I, Curutiu C, Holban AM et al. (2018). Aspects of gut microbiota and immune system interactions in infectious diseases, immunopathology, and cancer. Front Immunol. 9: 1830. https://doi.org/10.3389/fimmu.2018.01830; PMid:30158926 PMCid:PMC6104162
Liu C, Feng X, Li Q, Wang Y, Li Q, Hua M. (2016). Adiponectin, TNF-α and inflammatory cytokines and risk of type 2 diabetes: a systematic review and meta-analysis. Cytokine. 86: 100-109. https://doi.org/10.1016/j.cyto.2016.06.028; PMid:27498215
Luo X, Kong Q, Wang Y, Duan X, Wang P, Li C, Huan Y. (2021). Colonization of Clostridium butyricum in Rats and Its Effect on Intestinal Microbial Composition. Microorganisms. 9 (8): 1573. https://doi.org/10.3390/microorganisms9081573; PMid:34442652 PMCid:PMC8401576
Michalovich D, Rodriguez-Perez N, Smolinska S, Pirozynski M, Mayhew D, Uddin S et al. (2019). Obesity and disease severity magnify disturbed microbiome-immune interactions in asthma patients. Nat Commun. 10: 5711. https://doi.org/10.1038/s41467-019-13751-9; PMid:31836714 PMCid:PMC6911092
Nagata S, Chiba Y, Wang C, Yamashiro Y. (2017). The effects of the Lactobacillus casei strain on obesity in children: A pilot study. Benef Microbes. 8: 535-543. https://doi.org/10.3920/BM2016.0170; PMid:28618860
Nieto-Vazquez I, Fernández-Veledo S, De Alvaro C, Lorenzo M. (2008). Dual role of interleukin-6 in regulating insulin sensitivity in murine skeletal muscle. Diabetes. 57: 3211. https://doi.org/10.2337/db07-1062; PMid:18796617 PMCid:PMC2584126
Plomgaard P, Nielsen AR, Fischer CP, Mortensen OH, Broholm C, Penkowa M, et al. (2007). Associations between insulin resistance and TNF-alpha in plasma, skeletal muscle and adipose tissue in humans with and without type 2 diabetes. Diabetologia. 50: 2562-2571. https://doi.org/10.1007/s00125-007-0834-6; PMid:17928988
Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F et al. (2012). A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 490: 55-60. https://doi.org/10.1038/nature11450; PMid:23023125
Safavi SM, Farajian S, Kelishadi R, Mirlohi M, Hashemipour M. (2013). The effects of synbiotic supplementation on some cardio-metabolic risk factors in overweight and obese children: A randomized triple-masked controlled trial. Int J Food Sci Nutr. 64: 687-693. https://doi.org/10.3109/09637486.2013.775224; PMid:23477506
Sanna S, Van Zuydam NR, Mahajan A, Kurilshikov A, Vich Vila A, Võsa U et al. (2019). Causal relationships among the gut microbiome, short-chain fatty acids and metabolic diseases. Nature. Genetics. 51: 600-605. https://doi.org/10.1038/s41588-019-0350-x; PMid:30778224 PMCid:PMC6441384
Savchenko LG, Digtiar NI, Selikhova LG, Kaidasheva EI, Shlykova OA, Vesnina LE, Kaidashev IP. (2019). Liraglutide exerts an anti-inflammatory action in obese patients with type 2 diabetes. Rom J Intern Med. 57 (3): 233-240. https://doi.org/10.2478/rjim-2019-0003; PMid:30901315
Segain J-P, De La Blétière DR, Bourreille A, Leray V, Gervois N, Rosales C et al. (2000). Butyrate inhibits inflammatory responses through NFκB inhibition: implications for Crohn's disease. Gut. 47: 397-403. https://doi.org/10.1136/gut.47.3.397; PMid:10940278 PMCid:PMC1728045
Spranger J, Kroke A, Möhlig M, Hoffmann K, Bergmann MM, Ristow M et al. (2003). Inflammatory cytokines and the risk to develop type 2 diabetes. Diabetes. 52: 812. https://doi.org/10.2337/diabetes.52.3.812; PMid:12606524
Stierman B, Afful J, Carroll MD et al. (2021). National Center for Health Statistics. National Health and Nutrition Examination Survey 2017-March 2020 Prepandemic Data Files Development of Files and Prevalence Estimates for Selected Health Outcomes. Source : National Health Statistics Reports. Series: NHSR No.158. URL: https://stacks.cdc.gov/view/cdc/106273.
Valdes AM, Walter J, Segal E, Spector TD. (2018). Role of the gut microbiota in nutrition and health. BMJ. 361: k2179. https://doi.org/10.1136/bmj.k2179; PMid:29899036 PMCid:PMC6000740
Wang DQ, Portincasa P, Neuschwander-Tetri BA. (2013). Steatosis in the liver. Compr Physiol. 3 (4): 1493-1532. https://doi.org/10.1002/cphy.c130001; PMCid:PMC3622341
Wang HH, Lee DK, Liu M, Portincasa P, Wang DQ. (2020). Novel Insights into the Pathogenesis and Management of the Metabolic Syndrome. Pediatr Gastroenterol Hepatol Nutr. 23 (3): 189-230. https://doi.org/10.5223/pghn.2020.23.3.189; PMid:32483543 PMCid:PMC7231748
Wiciński M, Gębalski J, Gołębiewski J, Malinowski B. (2020). Probiotics for the Treatment of Overweight and Obesity in Humans-A Review of Clinical Trials. Microorganisms. 8 (8): 11-48. https://doi.org/10.3390/microorganisms8081148; PMid:32751306 PMCid:PMC7465252
Xu E, Pereira MMA, Karakasilioti I, Theurich S, Al-Maarri M, Rappl G et al. (2017). Temporal and tissue-specific requirements for T-lymphocyte IL-6 signalling in obesity-associated inflammation and insulin resistance. Nat Commun. 8: 14803. https://doi.org/10.1038/ncomms14803; PMid:28466852 PMCid:PMC5418621
Yan H, Qin Q, Chen J, Yan S, Li T, Gao X, Yang Y, Li A and Ding S. (2022). Gut Microbiome Alterations in Patients With Visceral Obesity Based on Quantitative Computed Tomography. Front Cell Infect Microbiol. 11: 823262. https://doi.org/10.3389/fcimb.2021.823262; PMid:35127566 PMCid:PMC8811355
Zhao L, Zhang F, Ding X, Wu G, Lam YY, Wang X et al. (2018). Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes. Science. 359: 1151-1156. https://doi.org/10.1126/science.aao5774; PMid:29590046
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Modern pediatrics. Ukraine
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The policy of the Journal “MODERN PEDIATRICS. UKRAINE” is compatible with the vast majority of funders' of open access and self-archiving policies. The journal provides immediate open access route being convinced that everyone – not only scientists - can benefit from research results, and publishes articles exclusively under open access distribution, with a Creative Commons Attribution-Noncommercial 4.0 international license (СС BY-NC).
Authors transfer the copyright to the Journal “MODERN PEDIATRICS. UKRAINE” when the manuscript is accepted for publication. Authors declare that this manuscript has not been published nor is under simultaneous consideration for publication elsewhere. After publication, the articles become freely available on-line to the public.
Readers have the right to use, distribute, and reproduce articles in any medium, provided the articles and the journal are properly cited.
The use of published materials for commercial purposes is strongly prohibited.
